Slide 1: 2Q26 Earnings Presentation
NASDAQ: HBIO 2Q26 Earnings Presentation John Duke, President & CEO Mark Frost, CFO & Treasurer August 11, 2026
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: Second Quarter Operating & Financial Summary
Second Quarter Operating & Financial Summary 2Q26 results: Revenue of $22.7 million, up 11% year-over-year driven by commercial traction across our telemetry and cellular and molecular technology (CMT) products Adjusted gross margin of 57%, lower than anticipated due to higher-than-expected sa
Slide 4: 2Q26 Highlights
2Q26 Highlights Income Statement Components ($ in millions except 2Q26 2Q25 percentages) Revenue 22.7 20.5 Gross Margin 12.6 11.5 % of Revenue 55.6% 56.4% Operating Expenses 13.6 12.4 % of Revenue 59.9% 60.4% Operating Income (Loss) (1.0) (0.8) % of Revenue (4.3%) (4.0%) Adjusted Operating Income* 1
Slide 5: 2Q26 Revenue Breakdown
2Q26 Revenue Breakdown HBIO Revenue 2Q26 2Q25 % Var Americas $11.4M $10.1M 13% Americas increase due to growth in CRO’s telemetry business EMEA growth due to CRO, pharma & distributors. EMEA up 1.5% on a EMEA $6.8M $6.6M 3% constant currency basis APAC $4.6M $3.7M 24% APAC increase primarily driven
Slide 6: 2Q26 Earnings, Cash & Debt
2Q26 Earnings, Cash & Debt $ Million except per share data EARNINGS (LOSS) PER SHARE* YTD CASH FLOW FROM OPERATIONS NET DEBT* $(0.05) $5.7 $(0.14) $33.5 $27.9 $(0.52) $(0.3) $(0.64) 2Q25 2Q26 2Q25 2Q26 YTD25 YTD26 As of 2Q25 As of 2Q26 GAAP ADJUSTED * Non-GAAP measure, see Slides 13-15 for reconcili
Slide 7: Outlook
Outlook 7
Slide 8: Outlook
Outlook REVENUE ADJ. GROSS MARGIN ADJ. EBITDA 3Q26 Revenue between $21.0M - $22.6M 3Q26 GM between 56% - 58% 3Q26 Adj. EBITDA between $1.5M - $2.5M FY26 Revenue growth between 3% - 5% FY26 GM between 57% - 59% FY26 Adj. EBITDA growth between 6% - 10% (Raised from 2% – 4%) (Updated from 58% - 60%) (M
Slide 9: Appendix
Appendix 9
Slide 10: Non-GAAP Reconciliation Table – Currency
Non-GAAP Reconciliation Table – Currency Three Months Ended June 30, Six Months Ended June 30, Non-GAAP revenue on a constant currency basis 2026 2025 Growth Rates 2026 2025 Growth Rates Total revenues $ 22,727 $ 20,450 11% 43,482 42,224 3% Effects of foreign currency rate fluctuations (153) - (791)
Slide 11: Non-GAAP Reconciliation Table – Gross Margin
Non-GAAP Reconciliation Table – Gross Margin Three Months Ended June 30, Six Months Ended June 30, Non-GAAP Gross Profit and Non-GAAP Gross Margin 2026 2025 2026 2025 Amount Margin Amount Margin Amount Margin Amount Margin (in thousands) Gross profit $ 12,630 55.6% $ 11,533 56.4% $ 24,874 57.2% $ 23
Slide 12: Non-GAAP Reconciliation Table – Adjusted Operating Income
Non-GAAP Reconciliation Table – Adjusted Operating Income Three Months Ended Six Months Ended June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025 GAAP operating loss $ (978) $ (819) $ (2,152) $ (50,487) Stock-based compensation 380 472 637 1,072 Acquired asset amortization 820 1,162 1,640 2,322
Slide 13: Non-GAAP Reconciliation Table – Adjusted EBITDA
Non-GAAP Reconciliation Table – Adjusted EBITDA Three Months Ended Six Months Ended June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025 GAAP net loss $ (2,910) $ (2,282) $ (6,334) $ (52,622) Stock-based compensation 380 472 637 1,072 Acquired asset amortization 820 1,162 1,640 2,322 Goodwill imp
Slide 14: Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt
Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt Three Months Ended Six Months Ended June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025 Diluted loss per share (GAAP) * $ (0.64) $ (0.52) $ (1.41) $ (11.91) Diluted adjusted loss per share * $ (0.14) $ (0.05) $ (0.47) $ (0.18) Weighted-ave
Slide 15: 15
15